Onderneming Harpoon Therapeutics, Inc.
Aandelen
HARP
US41358P2056
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
23,01 USD | +0,09% | 0,00% | +102,37% |
11/03 | Merck rondt overname van Harpoon Therapeutics af | MT |
11/03 | Merck Sharp & Dohme LLC heeft de overname afgerond van Harpoon Therapeutics, Inc. (NasdaqCM:HARP). | CI |
Vakgebied
Aantal werknemers: 53
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 59 | 11-10-18 |
Frank Lanza
DFI | Director of Finance/CFO | 62 | 01-04-19 |
Chatan Charan
CTO | Chief Tech/Sci/R&D Officer | - | 01-11-22 |
Holger Wesche
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-10-18 |
Luke Walker
CTO | Chief Tech/Sci/R&D Officer | - | 03-10-22 |
Haibo Wang
PRN | Corporate Officer/Principal | - | 01-08-23 |
Banmeet Anand
PRN | Corporate Officer/Principal | - | 06-07-22 |
Wendy Chang
HRO | Human Resources Officer | - | 06-07-22 |
Rachael Lester
PRN | Corporate Officer/Principal | - | 01-09-17 |
James B. Bucher
LAW | General Counsel | 59 | 26/12 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 59 | 11-10-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 21 397 205 | 16 465 638 ( 76,95 %) | 0 | 76,95 % |
Bedrijfsgegevens
Harpoon Therapeutics, Inc.
611 Gateway Boulevard Suite 400
94080, South San Francisco
+650 443 7400
http://www.harpoontx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |
- Beurs
- Aandelen
- Aandeel Harpoon Therapeutics, Inc. - Nasdaq
- Onderneming Harpoon Therapeutics, Inc.